Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has completed an additional investment of ₹2.5 million in its wholly owned subsidiary, Advanced Nutrazyme Private Limited (ANPL). This investment was made through participating in ANPL's rights issue, acquiring 2,50,000 Equity Shares of ₹10 each. Following this transaction, Advanced Enzyme's total investment in ANPL has risen to ₹3 million, represented by 3,00,000 Equity Shares of ₹10 each. This move strengthens the subsidiary's capital base and Advanced Enzyme's overall stake.

Advanced Enzyme Technologies Ltd announced its audited financial results for Q4 and the year ended March 2026. Consolidated revenue for FY26 increased by 17% to ₹7,458 million. Q4 FY26 revenue stood at ₹2,034 million, a 22% increase YoY. EBITDA for Q4 FY26 was ₹632 million, up 39% YoY, with an EBITDA margin of 31%. PAT for Q4 FY26 grew by 69% to ₹453 million, with a PAT margin of 22%. EPS for Q4 FY26 was ₹3.84, compared to ₹2.37 in Q4 FY25.

Advanced Enzyme Technologies Ltd's board has recommended a final dividend of 67.5%, which is ₹1.35 per equity share (face value of ₹2 each) for the financial year 2025-26. This is subject to shareholder approval at the upcoming 37th Annual General Meeting (AGM). The dividend, if approved, will be paid starting the second day from the AGM date. The record date and AGM date will be announced later. The board decided to defer the declaration of an interim dividend to preserve capital for strategic opportunities. The board also approved the reappointment of Mr. Mukund Madhusudan Kabra as Whole Time Director for another 5 years and the appointment of Mr. Pradip Bhailal Shah as an Additional Director (Independent) for a term of 5 years, both subject to shareholder approval. Additionally, the reappointment of M S K A & Associates LLP as Statutory Auditors for a second term of five years was approved, also subject to shareholder approval. The board approved the allotment of 49,350 Equity Shares pursuant to the Exercise of Options under Employees Stock Options Scheme 2022.

Advanced Enzyme Technologies Ltd's board has recommended a final dividend of ₹1.35 per equity share (67.5%) for FY26, subject to shareholder approval at the AGM. The board decided to defer the declaration of an interim dividend to preserve capital for strategic opportunities. The board also approved the reappointment of Mr. Mukund Madhusudan Kabra as Whole Time Director and the appointment of Mr. Pradip Bhailal Shah as an Additional Director (Independent). Additionally, MSKA & Associates LLP were reappointed as Statutory Auditors.

Advanced Enzyme Technologies Ltd has re-appointed Mr. Mukund Madhusudan Kabra as Whole Time Director for another term of 5 years, effective from April 01, 2027, subject to shareholder approval at the upcoming 37th AGM. The board also approved the appointment of Mr. Pradip Bhailal Shah as an Additional Director (Independent) effective from June 12, 2026, for a 5-year term, also subject to shareholder approval. The board recommended a final dividend of ₹ 1.35 per share and deferred the declaration of an interim dividend to preserve capital for strategic opportunities. Additionally, the re-appointment of M S K A & Associates LLP as Statutory Auditors for a second term was approved, along with the allotment of 49,350 Equity Shares under the ESOP scheme.

Advanced Enzyme Technologies Ltd has re-appointed M S K A & Associates LLP, Chartered Accountants, as the Statutory Auditors for a second term of five consecutive years, starting from the conclusion of the 37th Annual General Meeting (AGM) until the conclusion of the 42nd AGM. The board also approved the annual financial results for FY26, recommended a final dividend of ₹1.35 per share, re-appointed Mr. Mukund Madhusudan Kabra as Whole Time Director, and appointed Mr. Pradip Bhailal Shah as an Additional Director (Independent).

Advanced Enzyme Technologies Ltd's board approved the annual financial results (standalone and consolidated) for FY26 and recommended a final dividend of ₹1.35 per share (67.5%) subject to shareholder approval at the upcoming AGM. The board deferred the declaration of an interim dividend to preserve capital for strategic opportunities. The board also approved the reappointment of Mr. Mukund Madhusudan Kabra as Whole Time Director for another 5 years and the appointment of Mr. Pradip Bhailal Shah as an Additional Director (Independent) for 5 years, both subject to shareholder approval. Additionally, M S K A & Associates LLP were reappointed as Statutory Auditors for a second term of 5 years, also subject to shareholder approval. The board approved the allotment of 49,350 Equity Shares under ESOP 2022, increasing the paid-up share capital to ₹22,39,52,300.

Advanced Enzyme Technologies Ltd's board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. A final dividend of ₹1.35 per equity share (67.5%) has been recommended, subject to shareholder approval. The board also approved the reappointment of Mr. Mukund Madhusudan Kabra as Whole Time Director and the appointment of Mr. Pradip Bhailal Shah as an Additional Director (Independent). Additionally, MSKA & Associates LLP were reappointed as Statutory Auditors. The company also approved the allotment of 49,350 Equity Shares under ESOP 2022.

Advanced Enzyme Technologies Ltd has scheduled a Board of Directors meeting on May 9, 2026, to consider and approve the Annual Financial Statements (Standalone & Consolidated) for the fiscal year ended March 31, 2026, including the fourth-quarter results. The board will also consider recommending a final dividend for FY26 and/or declaring an interim dividend for FY27. The trading window remains closed until May 11, 2026.

Advanced Enzyme Technologies Ltd has announced the resignation of Mr. Dipak Roda, Senior Vice President - Marketing and Business Development, and Non-Executive Director of its Subsidiary, Advanced Enzytech Solutions Limited. The resignation will be effective from the close of business hours on April 09, 2026. The company informed the Stock Exchanges on March 11, 2026, about the resignation in accordance with the SEBI Listing Regulations. The resignation letter along with the reasons for resignation is enclosed as Annexure A.